Heterocyclic compounds as inhibitors of rotomase enzymes

A compound of the formula:

• or a pharmaceutically acceptable salt or solvate thereof, wherein
• R1 is triazolyl, isoxazolyl, oxadiazolyl, tetraazolyl, thiazolyl or thiadiazolyl, that is linked to the adjacent carbon atom by a ring carbon atom substituted by 1, 2 or 3 substituents each independently selected from C1-C6 alkyl, —X-aryl, X-het, —X—CO2R5 and —X—NR3R4 R2 is H, phenyl or C3-C7cycloalkyl, said phenyl or cycloalkyl being optionally benzo- or C3-C7cycloalkyl fused and optionally substituted, including in the benzo- or cycloalkyl-fused portion, by from 1 to 3 substituents each independently selected from C1-C6alkyl, C1-C6alkoxy, —OH, —(C1-C6alkylene) OH, halo and halo(C1-C6alkylene)—,
• or R2 is a 5-, 6- or 7-membered ring heterocyclic group containing either 1,2,3 or 4 nitrogen heteroatoms, or 1 oxygen or sulphur heteroatom and, optionally, 1 or 2 nitrogen heteroatoms, said heterocyclic group being saturated or partially or fully unsaturated, optionally benzo-fused and optionally substituted, including in the benzofused portion, by from 1 to 3 substituents each independently selected from C1-C6alkyl, C1-C6alkoxy, halo, halo(C1-C6alkylene- and —CO2R5, said R2 group being attached to W by by any mono- or bicyclic ring carbon atom or heteratom:
• R3 and R4 are either each independently selected from H, C1-C6alkyl C3-C6cycloalkyl and —(C1-C6alkylene)(C3-C6cycloalkyl), or, when taken together, represent unbranched C3-C6alkylene optionally containing 0 or NR5;
• R5 is H, C1-C6alkyl, C3-C6cycloalkyl, —(C1-C6alkyne)(C3-C6cycloalkyl) or —(C1-C6alkylene)aryl;
• A is unbranched C4 alkylene optionally substituted by C1-C6alkyl;
• W is a direct link, C1-C6alkylene or C2-C6alkenylene;
• X is direct link, C1-C6alkylene or (C0-C6alkylene)—Z—(C0-C6alkylene)-;
• Y is SO2;
• Z is O, S, —CR5NR3R4—, —CR5NR5(CO2R5)—, —CR5(aryl1)—, —NR5—, —NR5CO2, —CONR5— or —NR5CO—;
• “aryl” is phenyl optionally substituted by from 1 to 3 substituents each independently selected from C1-C6alkyl, C1-C6alkoxy, —(C1-C6alkylene)(C1-C6alkoxy), halo, halo(C1-C6alkylene)—, —NR3R4, —(C1-C6alkylene)NR3R4, —(C1-C6alkylene)OH, —O(—C1-C6alkylene)NR3R4 and -alkylene)(phthalimido);
• “aryl” is phenyl optionally substituted by from 1 to 3 substituents each independently selected from C1-C6alkyl, C1-C6alkoxy, —(C1-C6alkylene)(C1-C6alkoxy), halo and halo(C1-C6alkylene)—;
• and
• “het” is a 5-, 6-, or 7-membered ring heterocyclic group containing either 1,2,3 or 4 nitrogen heteroatoms, or 1 oxygen or sulphur heteroatom and, optionally, 1 or 2 nitrogen heteratoms, said heterocyclic group being saturated or partially or fully unsaturated, or “het” is azetidinyl, said “het” being optionally substituted by from 1 to 3 substituted each independently selected from C1-C6alkyl, C1-C6alkoxy, C3-C7 cycloalkyl, —(C1-C6alkylene)(C1-C6alkoxy), (C1-C6alkylene)(C3-C7cycloaklyl), halo, halo(C1-C6alkylene)—, —NR3R4, —CO2R5, —(C1-C6alkylene)aryl and (C1-C6alkylene)NR3R4:
• with the provisos that
• (a) the heteroaryl group of R1 is not substituted by C0-C6alkylene)—Z—(C0alkylene)(—OH or —C1-C4alkoxy or —CN or —NR3R4) when Z is O,S, —NR5—, —CONR5—.